Intron retention and nuclear loss of SFPQ are molecular hallmarks of ALSRaphaëlle Luisier(The Francis Crick Institute), Rickie Patani(National Hospital for Neurology and Neurosurgery)Nature CommunicationsMay 16, 201810.1038/s41467-018-04373-8Cited by 169SaveCiteExport RISWatch citationsRelated PapersAutologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study|The Lancet Neurology|2012|606Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis|Brain|2019|191The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments|Trials|2011|119